(March 20, 2019) Earlier this month, OCRA united advocates from across the country for Spring Advocacy Day on Capitol Hill. Together, this passionate group of survivors, caregivers and supporters used their collective voice to advocate for increased funding for ovarian cancer research and education. Learn more about our asks for Ovarian Cancer Research Program (OCRP) … Continued
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a history of successful breakthroughs, the program … Continued
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued
(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued
(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women … Continued
(February 26, 2019) Ovarian Cancer Research Alliance is pleased to announce Beth Y. Karlan, M.D as our new chair of OCRA’s Scientific Advisory Committee. Our Scientific Advisory Committee is comprised of 24 illustrious and respected leaders in research on treating women with ovarian cancer. Dr. Karlan is Professor and Vice Chair of Women’s Health Research … Continued
OCRA is pleased to announce we have earned our NINTH consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, organizational transparency, and accountability, as we continue to strive toward cures for ovarian cancer. A 4-star … Continued
February 4th is World Cancer Day. Today, millions of people across the globe raise a collective voice for progress. Against cancer in its many insidious forms, and for access to treatments and care for those who need it, no matter where they live. As the leading organization in the world fighting ovarian cancer from all … Continued
Another reason you don’t want to miss OCRA’s Turn Up the Heat! Not only does the event feature fabulous tastings from DC’s female culinary stars—we are thrilled to announce that the amazing Chef Elle Simone, from PBS’ America’s Test Kitchen will be our host! Elle Simone Scott began dazzling the culinary world in 2003, and … Continued
(January 10, 2019) We’re pleased to announce OCRA’s newest research grants of $5.25 million to 23 top scientists at 14 top medical centers. In 2019, with our other ongoing grants and programs, OCRA is investing nearly $9 million in our fight against ovarian cancer. “OCRA invests in medical research to cure ovarian cancer. Scientists need … Continued
Join our donors in supporting OCRA and your gift will have double the impact in the fight against ovarian cancer. Thanks to a generous year-end pledge from angel patrons and investment income to cover fundraising and administrative expenses, 100% of your gift will directly support OCRA’s research, education, patient support and advocacy programs. AND your … Continued
(December 21, 2018) This month, researchers in Boston published their findings on how PARP inhibitors (PARPi) cause a chain reaction of responses from the tumor and its environment. Study authors, including OCRA grantee Ursula Matulonis, MD, treated BRCA-1 deficient tumors with olaparib, a PARPi, and found that it began both a natural and medically induced … Continued
Get email updates about research news, action alerts, and ways to join the fight.
